Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2I13S)

• Drug Name: 4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole Drug Info
• Synonyms: CHEMBL118682; SCHEMBL4811439

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9923013
  TTD Drug ID: DM2I13S

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[2]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[3]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[4]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[5]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[6]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[7]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[8]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[9]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[10]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[11]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.3 (SCN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[6]
Aryl carboxamide derivative 1	DMTZRCW	N. A.	N. A.	Patented	[12]
Aryl carboxamide derivative 2	DM146TA	N. A.	N. A.	Patented	[12]
Pyrimidine derivative 1	DMN9VQM	N. A.	N. A.	Patented	[12]
Pyrrolo-pyridinone derivative 6	DMXGNP8	N. A.	N. A.	Patented	[12]
Pyrrolo-pyridinone derivative 5	DMK2FSY	N. A.	N. A.	Patented	[12]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[13]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[14]
PD-85639	DMNUKB4	N. A.	N. A.	Terminated	[6]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.3 (SCN3A)	TTAXZ0K	SCN3A_HUMAN	Inhibitor	[1]

References

• [1] 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3.
• [2] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [3] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [4] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [5] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [6] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [7] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [8] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [11] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [12] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [13] Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
• [14] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).